You are here

  • Home
  • Archive
  • Volume 21, Issue 3
  • In hypertensive patients with elevated risk of cardiovascular disease, targeting systolic blood pressure to less than 120 mm Hg significantly reduces the rate of fatal and non-fatal cardiovascular events as well as death from any cause

Article Text

Article menu
Download PDFPDF
Therapeutics/Prevention
Randomised controlled trial
In hypertensive patients with elevated risk of cardiovascular disease, targeting systolic blood pressure to less than 120 mm Hg significantly reduces the rate of fatal and non-fatal cardiovascular events as well as death from any cause
  1. Mina Owlia,
  2. Sripal Bangalore
  1. Department of Cardiology, University School of Medicine, New York, New York, USA
  1. Correspondence to : Dr Sripal Bangalore, Department of Cardiology, New York University School of Medicine, New York, NY 10016, USA; sripalbangalore{at}gmail.com

https://doi.org/10.1136/ebmed-2016-110397

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Wright JT Jr., Williamson JD, Whelton PK, et al., SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015;373:2103–16.OpenUrlCrossRefPubMed

    Context

    Hypertension is among the most significant modifiable risk factor for cardiovascular disease, yet there is considerable debate on the optimal blood pressure (BP) goal. Observational studies1 and the ACCORD trial2 suggest a target organ heterogeneity in that with lower systolic BP goals (<120 mm Hg) the risk of cerebrovascular events are reduced, but not coronary events. As such, systolic BP goals of <130, <140 or <150 mm Hg, have been proposed in the last decade by hypertension guideline societies.3 ,4

    Methods

    SPRINT was a randomised, controlled, open-label trial of targeted BP treatment to the standard BP goal (<140 mm Hg) compared …

    View Full Text

    Footnotes

    • Competing interests None declared.

    • Provenance and peer review Commissioned; internally peer reviewed.